Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
A new study led by Balázs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of suggestibility predicting an antidepressant response for patients receiving psilocybin therapy.
The study aimed to understand the link between pre-trial expectancy, suggestibility and response to treatment in a previously conducted clinical trial comparing escitalopram and COMPASS Pathways‘ (NASDAQ:CMPS) synthetic psilocybin, COMP360, in the treatment of 55 patients with Major Depressive Disorder (MDD.) Read more HERE.
The European Union has allocated 6.5 million euros ($7 million) from its Horizon Europe program to finance PsyPal, a multisite clinical study focusing on the use of psychedelic-assisted therapy. This initiative, led by the University Medical Centre Groningen (UMCG) in the Netherlands and in collaboration with HumanKindLabs, represents the EU's first investment in this area of research.
The study aims to evaluate the effectiveness of psilocybin therapy in reducing psychological and existential distress in patients with progressive, incurable diseases needing palliative care, specifically targeting conditions like chronic obstructive pulmonary disorder (COPD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and atypical Parkinson's disease (APD). Continue reading HERE.
The new treatments, given to two people under the guidance of Dr. Eli Kotler and Dr. Ted Cassidy, are framed within Australia’s Therapeutic Goods Administration (TGA) program authorizing psychiatrists to provide these medicines for specific mental health conditions.
Kotler and Cassidy, early graduates of Mind Medicine Australia (MMA) in psychedelic-assisted therapies, also supplied the psychedelics to the patients who were treated in Melbourne. Read more HERE.
Welcome to the inaugural episode of the Benzinga Psychedelics Podcast. In this exciting kickoff, we’re joined by Joel Latham, experienced biotech industry leader and CEO of Incannex Healthcare (NASDAQ:IXHL).
Dive into our engaging conversation as we explore Incannex’s strategic expansion into broader markets, its pioneering role in Australia’s psychedelic-assisted therapies and its management of a substantial drug portfolio. Listen here.
See Also: Last Week’s Edition Of ‘Psyched’
AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, Jan. 22 at $1.37, following prior weeks' opening at $1.44, $1.41 and $1.42 (Jan. 16, 8 and 2, respectively.)
On Friday, Jan. 26 it closed at $1.43, following prior weeks' closings at $1.37, $1.47 and $1.44 (Jan. 19, 12 and 5, respectively.)
Week's highest was $1.44 during Friday 26, vs. prior weeks' highest at $1.45, $1.64 and $1.62.
Week's lowest was opening price $1.37, vs. prior weeks' lowest at $1.39, $1.41 and $1.35.
Stock trading numbers above according to Benzinga Pro, our all-the-information-you-need streaming platform helping you invest smarter – Come join us and see for yourself!
Benzinga Cannabis Conferences are coming to Los Angeles. Join the Benzinga Cannabis Market Spotlight: California, and unlock the future of cannabis at the premier networking event in Culver City on February 22. Connect with top industry leaders, gain insider insights into the investment landscape and shape the evolving markets in California and beyond. Don't miss this chance to be at the forefront of the cannabis industry's growth and innovation! Join now.
Photo: Benzinga
Posted In: ATAI CMND CMPS CYBN DRUG ENVB GHRS IXHL MNMD NUMIF PSIL SEEL SILO